Jincheng Pharm(SZ:300233) Cai Jing Wang·2025-06-05 13:35Core Insights - The company Jin Cheng Pharmaceutical announced the receipt of drug registration certificates for its subsidiary's products, including Posaconazole enteric-coated tablets and injectable Cefoperazone sodium, enhancing its product portfolio in the antifungal and anti-infection sectors [1][2]. Group 1: Product Details - Posaconazole enteric-coated tablets are a second-generation triazole antifungal drug used for treating invasive aspergillosis and preventing infections caused by Aspergillus and Candida species, known for its broad antimicrobial spectrum, high activity, and good safety profile [1]. - Sales of Posaconazole enteric-coated tablets in China's public medical sector were reported as RMB 44.67 million, RMB 76.65 million, and RMB 201.33 million for the years 2021, 2022, and 2023, respectively [1]. - Injectable Cefoperazone sodium is indicated for treating infections caused by sensitive bacteria, including lower respiratory tract infections, urinary tract infections, and sepsis, and is sold in countries such as China, Japan, South Korea, Italy, and India [2]. Group 2: Market Position and Competitors - The main sales market for injectable Cefoperazone sodium is China, with reported sales of RMB 3.442 billion, RMB 4.257 billion, and RMB 4.494 billion for the years 2021, 2022, and 2023, respectively [2]. - Approved manufacturers for Posaconazole enteric-coated tablets in China include Qilu Pharmaceutical (Hainan) Co., Ltd. and Sichuan Kelun Pharmaceutical Co., Ltd. [1]. - Approved manufacturers for injectable Cefoperazone sodium include Chengdu Better Pharmaceutical Co., Ltd., Qilu Anti-Pharmaceutical Co., Ltd., and Harbin Pharmaceutical Group [2]. Group 3: Strategic Implications - The approval of Posaconazole enteric-coated tablets and injectable Cefoperazone sodium enriches the company's product line, which is expected to enhance its market competitiveness in the antifungal and anti-infection fields [2].